

AUG 26 2005

PATENT & TRADEMARK OFFICE

plus sign (+) in this box

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/760,509
				Filing Date	01-20-2004
				First Named Inventor	PETRY
				Group Art Unit	1624
				Examiner Name	BALASUBRAMANIAN, Venkataraman
				Attorney Docket Number	DEAV2003/0003 - US - NP
Sheet	1	of	4		

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
W		WO	00/40569		HODSON, et. al.	07-13-2000		
W		WO	00/64876		JAYYOSI, et. al.	11-02-2000		
W		WO	00/66585		HORVATH, et. al.	11-09-2000		
W		WO	00/71549		BROUGH, et. al.	11-30-2000		
W		WO	01/09111		BRINER, et. al.	02-08-2001		
W		WO	01/83451		IKUTA, et. al.	11-08-2001		
W		WO	97/26265		NIELSEN, et. al.	07-24-1997		
W		WO	97/41097		LOHRAY, et. al.	11-06-1997		
W		WO	98/08871		KNUDSEN, et. al.	03-05-1998		
W		WO	99/03861		NIELSEN, et. al.	01-28-1999		

Examiner Signature	V. Balasubramanian	Date Considered	11/8/06
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/760,509
			Filing Date	01-20-2004
			First Named Inventor	PETRY
			Group Art Unit	1624
			Examiner Name	BALASUBRAMANIAN, Venkataraman
			Attorney Docket Number	DEAV2003/0003 - US - NP
Sheet	3	of	4	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
M		ASAKAWA, A., et. al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice, Hormone and Metabolic Research, (2001) Vol. 33, No. 9, pp. 554 - 558	
M		LEE, D. W., et. al., Leptin agonists as a potential approach to the treatment of obesity, Drugs of the Future, 2001, Vol. 26(9), pp 873-881	
M		LIOA, T., et. al., Synthesis of 1-Demethyltoxoflavin (8-Demethylfervenuin)1, Journal of Organic Chemistry, Vol. 31, (1965) pp. 900-902	
M		TONKS, N.K., et. al., Characterization of the Major Protein-tyrosine-phosphatases of Human Placenta, Journal of Biological Chemistry, Vol. 263, No. 14, May 15, 1988, pp. 6731-6737	
M		OKADA, H., et. al., Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas, Chem. Pharm. Bull., (1994), Vol. 42, No. 1, pp. 57 - 61	
M		TYLE, P., et. al., Iontophoretic Devices for Drug Delivery, Pharmaceutical Research, Vol. 3, No. 6, 1986	
M		LANZETTA, P.A., et. al., An Improved Assay for Nanomole Amounts of Inorganic Phosphate, Analytical Biochemistry, Vol. 100, 1979, pp. 95-97	
M		SALVADOR, J., et. al., Perspectives in the therapeutic use of leptin, Expert Opinion on Pharmacotherapy 2001, 2(10), 1615-1622	
M		BURKE, T.R., et. al., Small Molecule Interactions with Protein-Tyrosine Phosphatase PTP1B and Their Use in Inhibitor Design, Biochemistry, Vol. 35, 1996, pp. 15989-15996	
M		CROMLISH, W., et. al., Selective Inhibition of Cyclooxygenase-1 and -2 Using Intact Insect Cell Assays, Biochemical Pharmacology, Vol 52, 1996, pp. 1777-1785	

Examiner Signature	V. Balasubramanian	Date Considered	11/8/06
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/760,509		
		Filing Date	01-20-2004		
		First Named Inventor	PETRY		
		Group Art Unit	1624		
		Examiner Name	BALASUBRAMANIAN, Venkataraman		
Sheet	4	of	4	Attorney Docket Number	DEAV2003/0003 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
W		YONEDA, F., et. al., Antitumor Agent, Patent Abstracts of Japan Vol. 1998-01-30	
W		YONEDA, F., et. al., A Convenient Synthesis of Toxoflavins, Toxoflavin 4-Oxides and 1-Demethyltoxoflavins, Chemical and Pharmaceutical Bulletin Vol.23, No.9 (1975) pp. 2001-2009	
W		ZUNFT, H., et. al., Carob Pulp Preparation for Treatment of Hypercholesterolemia, Advances in Therapy, 2001, Vol. 18(5), pp 230-236	

Examiner Signature	V. Balasubramanian	Date Considered	11/8/06
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.